Lord, Abbett & Co. LLC Adaptimmune Therapeutics PLC Transaction History

Lord, Abbett & Co. LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$4.9 - $6.83 $2.29 Million - $3.19 Million	-466,668 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$4.0 - $9.2 $66,016 - $151,836	-16,504 Reduced 3.42%	466,668 $2.52 Million
Q3 2020 Nov 12, 2020	SELL	$7.66 - $10.78 $186,513 - $262,482	-24,349 Reduced 4.8%	483,172 $3.86 Million
Q2 2020 Aug 14, 2020	BUY	$2.58 - $12.1 $1.31 Million - $6.14 Million	507,521 New	507,521 $5.08 Million

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $88.2M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.